ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogsGuiqiang Wang, Jinzi J. Wu, Yimin Cui et al.|Journal of Hepatology|2022Cited by 20
Twelve‐week ravidasvir plus ritonavir‐boosted danoprevir and ribavirin for non‐cirrhotic HCV genotype 1 patients: A phase 2 studyJia‐Horng Kao, Jinzi J. Wu, Ming‐Yao Chen et al.|Journal of Gastroenterology and Hepatology|2018Cited by 14